Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference

  //health-fitness.news-articles.net/content/2012/ .. -company-32nd-annual-health-care-conference.html
  Published in Health and Fitness on Thursday, March 1st 2012 at 4:10 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference -- SEATTLE, March 1, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about OMER

SEATTLE, March 1, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: [ OMER ]), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference taking place in Boston, Massachusetts next week.  The presentation is scheduled for Wednesday, March 7, 2012 at 11:20 a.m. Eastern Time.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at [ www.omeros.com ].  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

RELATED LINKS
[ http://www.omeros.com ]